Revelation Biosciences (NASDAQ:REVB) Posts Earnings Results, Misses Expectations By $0.04 EPS

Posted by Don Miller on Aug 8th, 2026

Revelation Biosciences (NASDAQ:REVB – Get Free Report) announced its earnings results on Friday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.04), FiscalAI reports.

Revelation Biosciences Stock Performance

Revelation Biosciences stock traded up $0.02 during mid-day trading on Friday, reaching $1.14. 25,572 shares of the company were exchanged, compared to its average volume of 42,163. The firm’s 50-day simple moving average is $1.04 and its two-hundred day simple moving average is $1.27. Revelation Biosciences has a twelve month low of $0.88 and a twelve month high of $11.72. The firm has a market cap of $4.46 million, a PE ratio of -0.09 and a beta of -0.15.

Institutional Investors Weigh In On Revelation Biosciences

An institutional investor recently bought a new position in Revelation Biosciences stock. Geode Capital Management LLC acquired a new stake in Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 34,019 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned about 2.15% of Revelation Biosciences at the end of the most recent reporting period. Institutional investors own 12.80% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

View Our Latest Stock Analysis on REVB

About Revelation Biosciences

(Get Free Report)

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.